Categories
Change Password!
Reset Password!
Bilateral severe renal artery stenosis (≥70%) identifies the subgroup most likely to benefit from kidney revascularization, helping refine patient selection and advance personalized care in ARVD.
A major pooled analysis drawing on the ASTRAL Trial and the Salford ARVD Study is challenging long-held assumptions about revascularization in atherosclerotic renal artery stenosis. While earlier randomized trials discouraged routine use of angioplasty and stenting, this novel investigation suggests the story is far from settled—and that the key lies in identifying the right patients.
Analyzing 1,644 atherosclerotic renovascular disease (ARVD)-affected individuals (806 ASTRAL; 838 Salford cohort) with a median age of 72 years, researchers compared outcomes between medical therapy alone and medical therapy combined with revascularization. Patients were carefully stratified by stenosis severity and clinical phenotype, including high-risk features such as advanced chronic kidney disease, rapid decline in kidney function, resistant hypertension, and heart failure.
The findings draw a clear line: benefit from revascularization is largely confined to those with bilateral severe renal artery stenosis (≥70%). In this group, intervention was associated with a prominent 30% reduction in the risk of progression to end-stage kidney disease, cardiovascular events, or death (hazard ratio [HR] 0.70). The effect was even more striking among those with rapidly progressive kidney disease, where the risk reduction reached 61% (HR 0.39).
In contrast, those without bilateral severe disease—whether due to unilateral involvement or less critical narrowing—derived no measurable benefit from revascularization, regardless of how high-risk their clinical profile appeared. This finding reinforces why earlier trials, which did not fully differentiate these subgroups, may have underestimated the procedure’s value in select populations. Although the inclusion of observational data remains a limitation, the consistency of results across datasets adds weight to the conclusions.
The message is increasingly clear: revascularization must not be abandoned—but it must be targeted. This study reframes clinical decision-making in renovascular disease, shifting away from a one-size-fits-all strategy toward a more individualized approach. For those with bilateral severe disease—particularly those with rapidly worsening kidney function or coexisting heart failure—revascularization may offer meaningful long-term benefit, while for others, optimal medical therapy remains the cornerstone of care.
Kidney Medicine
Patient Selection for Revascularization of Atherosclerotic Renal Artery Stenosis: Comparing the Importance of Stenosis Severity and Clinical Phenotype
Darren Green et al.
Comments (0)